Article Text

Download PDFPDF
Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic review

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.


  • Twitter Follow Muhammad Abdul Hadi @Hadi_PharmPrac

  • Contributors Conception and design: MAH, GAM, PGC. Data extraction: MAH, GAM. Analysis and interpretation of data: MAH, GAM. Drafting of the article: MAH, GAM. Critical revision of the article for important intellectual content: PGC. Final approval for publication: MAH, GAM, PGC.

  • Funding No funding was obtained from any public or private funding source for the purpose of this study. PGC is supported in part through the NIHR Leeds Biomedical Research Centre.

  • Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

  • Competing interests PGC is on the speaker’s bureau of or has acted as a consultant for AbbVie, Bioiberica, BMS, Flexion, Lilly, Merck Serono, Novartis, Pfizer and Roche.

  • Provenance and peer review Not commissioned; externally peer reviewed.